Aminoindoles, a Novel Scaffold with Potent Activity against Plasmodium falciparum Articles uri icon

authors

  • BARKER, ROBERT H., JR.
  • URGAONKAR, SAMEER
  • MAZITSCHEK, RALPH
  • CELATKA, CASSANDRA
  • SKERLJ, RENATO
  • CORTESE, JOFEPH F.
  • TYNDALL, ERIN
  • LIU, HANLAN
  • CROMWELL, MANDY
  • SIDHU, AMAR BIR
  • GUERRERO-BRAVO, JOSE E.
  • CRESPO-LLADO, KEILA N.
  • SERRANO, ADELFA E.
  • LIN, JING-WEN
  • JANSE, CHRIS J.
  • KHAN, SHAHID M.
  • DURAISINGH, MANOJ
  • COLEMAN, BRADLEY I.
  • ANGULO BARTUREN, ÍÑIGO
  • JIMÉNEZ DÍAZ, MARÍA BELÉN
  • MAGAN, NOEMI
  • GOMEZ, VANESA
  • FERRER BAZAGA, SANTIAGO
  • SANTOS MARTINEZ, MARIA
  • WITTLIN, SERGIO
  • PAPASTOGIANNIDIS, PETROS
  • O'SHEA, THOMAS
  • KLINGER, JEFREY D.
  • BREE, MARK
  • LEE, EDWARD
  • LEVINE, MIKAELA
  • WIEGAND, ROGER C.
  • MUNOZ, BENITO
  • WIRTH, DYAMM F.
  • CLARDY, JON
  • BATHURST, IAN
  • SYBERTZ, EDMUND

publication date

  • June 2011

start page

  • 2612

end page

  • 2622

issue

  • 6

volume

  • 55

International Standard Serial Number (ISSN)

  • 0066-4804

Electronic International Standard Serial Number (EISSN)

  • 1098-6596

abstract

  • This study characterizes aminoindole molecules that are analogs of Genz-644442. Genz-644442 was identified as a hit in a screen of similar to 70,000 compounds in the Broad Institute's small-molecule library and the ICCB-L compound collection at Harvard Medical School. Genz-644442 is a potent inhibitor of Plasmodium falciparum in vitro (50% inhibitory concentrations [IC(50)s], 200 to 285 nM) and inhibits P. berghei in vivo with an efficacy of > 99% in an adapted version of Peters' 4-day suppressive test (W. Peters, Ann. Trop. Med. Parasitol. 69: 155-171, 1975). Genz-644442 became the focus of medicinal chemistry optimization; 321 analogs were synthesized and were tested for in vitro potency against P. falciparum and for in vitro absorption, distribution, metabolism, and excretion (ADME) properties. This yielded compounds with IC(50)s of approximately 30 nM. The lead compound, Genz-668764, has been characterized in more detail. It is a single enantiomer with IC(50)s of 28 to 65 nM against P. falciparum in vitro. In the 4-day P. berghei model, when it was dosed at 100 mg/kg of body weight/day, no parasites were detected on day 4 postinfection. However, parasites recrudesced by day 9. Dosing at 200 mg/kg/day twice a day resulted in cures of 3/5 animals. The compound had comparable activity against P. falciparum blood stages in a humanengrafted NOD-scid mouse model. Genz-668764 had a terminal half-life of 2.8 h and plasma trough levels of 41 ng/ml when it was dosed twice a day orally at 55 mg/kg/day. Seven-day rat safety studies showed a no-observableadverse- effect level (NOAEL) at 200 mg/kg/day; the compound was not mutagenic in Ames tests, did not inhibit the hERG channel, and did not have potent activity against a broad panel of receptors and enzymes. Employing allometric scaling and using in vitro ADME data, the predicted human minimum efficacious dose of Genz-668764 in a 3-day once-daily dosing regimen was 421 mg/day/70 kg, which would maintain plasma trough levels above the IC(90) against P. falciparum for at least 96 h after the last dose. The predicted human therapeutic index was approximately 3, on the basis of the exposure in rats at the NOAEL. We were unable to select for parasites with > 2-fold decreased sensitivity to the parent compound, Genz-644442, over 270 days of in vitro culture under drug pressure. These characteristics make Genz-668764 a good candidate for preclinical development.

subjects

  • Biology and Biomedicine

keywords

  • human liver-microsomes; in-vitro; malaria parasites; rodent malaria; berghei; resistance; identification; erythrocytes; artemisin; ininfection